Skip to main content

Market Overview

PerkinElmer Expands Into Cell Biology With $260M Nexcelom Bioscience Acquisition

PerkinElmer Expands Into Cell Biology With $260M Nexcelom Bioscience Acquisition
  • PerkinElmer Inc (NYSE: PKIhas agreed to acquire privately-held Nexcelom Bioscience, a provider of instruments, workstations, assays, cell reagents & consumables with application in the development of cell and gene and immuno-oncology therapies, virology drugs, and vaccines.
  • The deal value of $260 million will be paid using cash on hand. As of March 31, the company reported cash and equivalents of $988 million.
  • The agreement to acquire Nexcelom comes five months after PerkinElmer added Horizon Discovery, a gene editing, and gene modulation tool provider.
  • Nexcelom has around 130 employees, with expected 2021 revenues of nearly $40 Million.
  • The transaction is expected to close during the second quarter of 2021.
  • PerkinElmer's existing biologics, vaccine, and cell & gene research solutions feature in vivo and cell painting screening technologies; immunoassays; CRISPR, RNAi, DNA tools and custom cell lines; cell plate readers and advanced automation; microfluidics and analytical platforms.
  • Price Action: PKI shares closed at $137.86 on Wednesday.

Related Articles (PKI)

View Comments and Join the Discussion!

Posted-In: Briefs Cell BiologyM&A News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at